Zentalis Pharmaceuticals, Inc.ZNTLNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | -100.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | -100.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | -579.53% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | -578.57% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | -578.57% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.71% | +0.67% | +1.10% | +1.34% | +1.45% |
| Weighted Average Shares Diluted Growth | +0.71% | +0.67% | +0.68% | +1.34% | +1.45% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -23.06% | -23.43% | -31.11% | -28.47% | -27.38% |
| Book Value per Share Growth | -26.97% | -23.40% | -36.32% | -29.20% | -29.65% |
| Debt Growth | -5.31% | -6.82% | -14.78% | -14.39% | -15.16% |
| R&D Expense Growth | -21.26% | -36.05% | -45.05% | -42.94% | -37.68% |
| SG&A Expenses Growth | -8.43% | +144.45% | -31.37% | -56.47% | -26.18% |